NCT06766929View on ClinicalTrials.gov

A Phase I Clinical Study of VSA012 in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

VSA012

subcutaneous injection

DRUG

Placebo

subcutaneous injection

All Listed Sponsors

lead

Visirna Therapeutics HK Limited

INDUSTRY